Academic Journal
View in EDS

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial

Bibliographic Details
Title: Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial
Authors: Giugliano, Robert P., Mach, Francois, Zavitz, Kenton, Kurtz, Christopher, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R., Sabatine, Marc S., Sever, Peter S., Honarpour, Narimon, Wasserman, Scott M., Ott, Brian R.
Source: Clinical Cardiology; Feb2017, Vol. 40 Issue 2, p59-65, 7p
Database: Complementary Index
More Details
ISSN:01609289
DOI:10.1002/clc.22678
Published in:Clinical Cardiology
Language:English